000661.SHE Changchun High & New Technology Industries Group Inc
- Market cap
- CNY 29.7B
- P/E
- -
- P/B
- 1.26x
- ROE
- 3.5%
- Dividend yield
- 3.65%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000661.SHE undervalued?
Graham numberThe Graham number of Changchun High & New Technology Industries Group Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Changchun High & New Technology Industries Group Inc fundamental analysis
No fundamental analysis for Changchun High & New Technology Industries Group Inc yet.
Changchun High & New Technology Industries Group Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Changchun High & New Technology Industries Group Inc
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal spray live attenuated influenza; xueshuanxinmaining tablet; and yinhuamiyanlin…
Full company profileChangchun High & New Technology Industries Group Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Changchun High & New Technology Industries Group Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.90B | 4.10B | 5.37B | 7.37B | 8.58B | 10.7B | 12.6B | 14.6B | 13.5B | 12.1B | 11.0B |
| Gross Profit | 2.30B | 3.36B | 4.57B | 6.27B | 7.43B | 9.31B | 11.0B | 12.4B | 11.4B | 9.92B | 8.71B |
| Operating Income | 811M | 1.14B | 1.81B | 2.88B | 3.94B | 4.72B | 4.97B | 5.59B | 3.30B | 870M | 1.47B |
| EBITDA | 859M | 1.19B | 1.79B | 2.91B | 3.95B | 4.86B | 5.32B | 6.14B | 4.07B | 804M | 943M |
| Net Income | 485M | 662M | 1.01B | 1.78B | 3.05B | 3.76B | 4.14B | 4.53B | 2.58B | 155M | 781M |
| EPS | 1.43 | 1.95 | 2.96 | 5.14 | 7.46 | 9.17 | 10 | 11 | 6.42 | 0.38 | 1.92 |
| Balance Sheet | |||||||||||
| Total Assets | 6.20B | 7.35B | 9.43B | 12.7B | 16.9B | 22.5B | 26.0B | 30.7B | 31.1B | 30.1B | 31.3B |
| Total Liabilities | 1.75B | 2.15B | 3.09B | 3.91B | 4.58B | 5.28B | 5.22B | 5.71B | 4.95B | 5.21B | 5.94B |
| Shareholders' Equity | 3.90B | 4.43B | 5.31B | 8.08B | 10.9B | 14.6B | 18.0B | 22.1B | 23.0B | 22.0B | 22.5B |
| Cash & Short-term Investments | 2.61B | 2.36B | 2.47B | 3.95B | 3.97B | 5.75B | 5.58B | 7.59B | 6.12B | 2.16B | 3.51B |
| Total Debt | 84.7M | 72.5M | 267M | 583M | 1.48B | 1.29B | 1.22B | 814M | 1.52B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 308M | 381M | 884M | 1.93B | 1.11B | 3.33B | 2.83B | 5.11B | 3.10B | 802M | - |
| Capital Expenditure | 185M | 231M | 686M | 845M | 1.10B | 2.23B | 2.09B | 2.10B | 2.18B | 2.20B | 1.27B |
| Free Cash Flow | 123M | 150M | 198M | 1.09B | 13.9M | 1.10B | 735M | 3.01B | 923M | -1.40B | 1.95B |
| Ratios | |||||||||||
| ROE | 12.4% | 15.0% | 19.0% | 22.0% | 27.9% | 25.8% | 22.9% | 20.5% | 11.2% | 0.7% | 3.5% |
| ROA | 7.8% | 9.0% | 10.7% | 14.0% | 18.0% | 16.7% | 15.9% | 14.7% | 8.3% | 0.5% | 2.5% |
| Net Profit Margin | 16.7% | 16.1% | 18.7% | 24.1% | 35.5% | 35.0% | 32.8% | 31.1% | 19.2% | 1.3% | 7.1% |
| Debt to Equity | 0.02x | 0.02x | 0.05x | 0.07x | 0.14x | 0.09x | 0.07x | 0.04x | 0.07x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Changchun High & New Technology Industries Group Inc dividends
- Dividend yield
- 3.65%
- Forward dividend
- 0.16 CNY
- Payout ratio
- 699.2%
- Ex-dividend date
- May 25, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.08B | 2.66 | 699.2% |
| 2024 | CNY 1.84B | 4.57 | 71.2% |
| 2023 | CNY 405M | 0.99 | 8.9% |
| 2022 | CNY 322M | 0.79 | 7.8% |
| 2021 | CNY 324M | 0.79 | 8.6% |
| 2020 | CNY 216M | 0.53 | 7.1% |
| 2019 | CNY 119M | 0.34 | 6.7% |
| 2018 | CNY 138M | 0.40 | 13.7% |
| 2017 | CNY 157M | 0.46 | 23.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jun 9, 2020.
Who owns Changchun High & New Technology Industries Group Inc
- Insiders 29.15%
- Institutions 7.55%
- Public & others 63.30%
- Shares outstanding 408M
- Free float 284M
Changchun High & New Technology Industries Group Inc company profile
- Company name
- Changchun High & New Technology Industries Group Inc
- Ticker
- 000661.SHE
- ISIN
- CNE0000007J8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Dec 3, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,080
- Fiscal year end
- December
- Address
- Building B, Changchun, China, 130012
- Phone
- 86 431 8055 7027
- Website
- ccht.jl.cn
About Changchun High & New Technology Industries Group Inc
Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal spray live attenuated influenza; xueshuanxinmaining tablet; and yinhuamiyanling tablet. It also develops real estate properties. The company was founded in 1993 and is based in Changchun, China.
Changchun High & New Technology Industries Group Inc management
8- Dr. Lei Jin Ph.D.GM & Director · born 1965
- Mr. Xing Gong ZhuDeputy GM & CFO · born 1966
- Mr. Zhigang WangDeputy GM & Director · born 1972
- Mr. Xiufeng LiDeputy GM & Director · born 1968
- Mr. Hong Yu LiBoard Secretary · born 1985
- Mr. Peng YeDeputy General Manager · born 1968
- Mr. Bing JieDeputy General Manager · born 1974
- Mr. Yan ZhangDeputy General Manager · born 1970